Sharemaestro Newsreel

Smith+Nephew (SNN) lifts H1 2026 profit but cuts revenue growth outlook

Smith+Nephew reported a higher profit for the first half of 2026, with revenue reaching $3,097 million, an increase of 4.6% year-on-year, and trading profit up 8.1% to $566 million. Despite this profit growth, the company revised its full-year underlying revenue growth guidance downwards from …

Amgen (AMGN) Opens New Science And Innovation Center In Hyderabad

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Amgen (NasdaqGS:AMGN) announced the opening of a new Science and Innovation Center in Genome Valley, Hyderabad, expanding its global research and development presence. The Hyderabad center is …

Renaissance Technologies LLC Acquires New Position in Biohaven Ltd. $BHVN

Renaissance Technologies LLC has acquired a new position in Biohaven Ltd. (NYSE:BHVN), purchasing 160,952 shares valued at approximately $1.36 million. This move comes as institutional investors collectively own 88.78% of Biohaven, with several major funds significantly increasing their stakes. Despite missing quarterly EPS expectations, …

Ligand Pharmaceuticals (LGND) Stock Trades Below Fair Value Following A 337% Run

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Ligand Pharmaceuticals stock has surged over the past five years, yet the valuation signals are split, with a Discounted Cash Flow (DCF) intrinsic value estimate …

Lumexa Imaging (LMRI) Stock Jumps As Profit Arrives But Margin Doubts Persist

Polar Capital discloses 5.28% Arcutis Biotherapeutics (ARQT) ownership in Schedule 13G

Polar Capital Holdings Plc and Polar Capital LLP have disclosed a 5.28% ownership stake in Arcutis Biotherapeutics, Inc. (ARQT) through a Schedule 13G filing. The investment firm beneficially owns 6,606,945 shares, with sole voting and dispositive power, based on Arcutis's 125,083,374 outstanding shares as …

Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress

Adlai Nortye Ltd. announced its unaudited financial results for the first half of 2026, reporting a significant decrease in net loss to US$5.3 million and a rise in revenue to US$13.1 million, primarily from a licensing agreement. The company highlighted operational progress in its …

Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock?

Key Points Q2 revenue fell, but last year included a large one-time payment. There were other signs of trouble in the earnings report. Wall Street is still bullish on the shares.10 stocks we like better than Ionis Pharmaceuticals › Shares of Ionis Pharmaceuticals(NASDAQ: IONS) …

How Cigna’s Dividend Hike And Jefferies’ Downgrade At Cigna Group (CI) Has Changed Its Investment Story

Cigna Group recently declared a US$1.56 per share cash dividend with an ex-dividend date of September 8, 2026, while Jefferies downgraded its rating to 'hold' due to anticipated 2027 earnings headwinds. This situation highlights a tension between management's commitment to returning capital to shareholders …

Surgery Partners (SGRY) Reaffirmed Guidance On Revenue Growth, Is It Still A Bargain?

Surgery Partners (SGRY) has garnered attention after reaffirming its full-year guidance and emphasizing a focus on higher acuity procedures, despite continued net losses. The company's stock is considered 15.4% undervalued, with a fair value estimated at $17.95, driven by the migration of high-acuity surgical …

Is BioLife Solutions (BLFS) A Bargain After Its Earnings Turnaround?

Boston Scientific (BSX) Faces Growth Slowdown in Key Businesses

Parnassus Investments, an investment management company, released the "Parnassus Core Equity Fund" second quarter of 2026 investor letter. A copy of the letter can be downloaded here. The fund returned 16.83% in the second quarter of 2026, outperforming the S&P 500's 15.20% gain. Performance …

Thomasville National Bank Buys Shares of 26,575 AbbVie Inc. $ABBV

Thomasville National Bank acquired a new stake of 26,575 shares in AbbVie Inc., valued at approximately $6.687 million, during the second quarter. AbbVie continues to show strong institutional interest, positive analyst sentiment with a "Moderate Buy" consensus and an average price target of $275.50, …

Signaturefd LLC Buys 22,148 Shares of Novo Nordisk A/S $NVO

Saratoga Research & Investment Management Sells 200,320 Shares of Novo Nordisk A/S $NVO

Merit Financial Group LLC Has $53.25 Million Stock Position in Johnson & Johnson $JNJ

Johnson & Johnson $JNJ Stock Holdings Decreased by Gateway Investment Advisers LLC

Monument Capital Management Decreases Stake in Gilead Sciences, Inc. $GILD

Monument Capital Management significantly reduced its stake in Gilead Sciences by 56.1% in the second quarter, selling over 15,000 shares. Despite this, institutional investors collectively own 83.67% of the company, and analysts maintain a "Moderate Buy" consensus with an average price target of $158.04. …

Mirae Asset Global Investments Co. Ltd. Increases Stake in Novo Nordisk A/S $NVO

Bernstein Adjusts PT on Regeneron Pharmaceuticals to $756 From $753, Maintains Market Perform Rating

Bernstein has increased its price target for Regeneron Pharmaceuticals (REGN) to $756 from $753, while maintaining a "Market Perform" rating on the stock. This adjustment reflects a modest change in the analyst's valuation, indicating a continued neutral stance on the company's stock performance. The …

17,243 Shares in Johnson & Johnson $JNJ Bought by Thomasville National Bank

Arcutis Biotherapeutics (NASDAQ:ARQT) Matches Navellier's Growth Playbook With Accelerating Fundamentals

Rallybio Corp (RLYB) sees Balyasny group report 0% ownership in 13G/A

Nektar Therapeutics (NKTR) adds $1.02B cash while posting $85.5M loss

MiNK Therapeutics (NASDAQ:INKT) Stock Rating Lowered by Zacks Research

QV Investors Inc. Acquires 81,870 Shares of Novo Nordisk A/S $NVO

Johnson & Johnson $JNJ Shares Bought by Interchange Capital Partners LLC

Bristol Myers Squibb announces new $2.3bn campus in the US

Bristol Myers Squibb has announced a new $2.3 billion multi-modal manufacturing campus in Houston, Texas, creating nearly 500 skilled jobs. This investment is part of BMS's $40 billion commitment to the US, aiming to accelerate the delivery of next-generation medicines. The campus's modular design …

Zacks.com featured highlights include BioMarin Pharmaceutical, Invesco, Centene Corporation, Hewlett Packard Enterprise and Gibraltar Industries

For Immediate Release Chicago, IL – August 14, 2026 – Stocks in this week's article are BioMarin Pharmaceutical BMRN, Invesco IVZ, Centene Corporation CNC, Hewlett Packard Enterprise HPE and Gibraltar Industries ROCK. 5 Undervalued Price-to-Book Stocks Worth Buying in August There are several different …

Centene (CNC) Stock Still Looks Like A Bargain As Shares Jumped 145%

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Centene stock has surged over the past year, yet the current checks still suggest it leans on the cheap side, so investors are weighing how …

Eton Pharmaceuticals jumps on strong Q2 print, 2026 guidance

Shares in Eton Pharmaceuticals (ETON [https://seekingalpha.com/symbol/ETON]) rallied 25% in premarket trading on Friday, driven by a solid quarterly print and 2026 revenue forecast, which the company said would exceed $145M while targeting adjusted EBITDA margin above 35%. Chief executive officer Sean Brynjelsen said the …

ANI Pharmaceuticals (ANIP) Could Be 34% Undervalued As Earnings And Guidance Hold

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Average Recommendation of "Moderate Buy" from Brokerages

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) has received an average "Moderate Buy" recommendation from analysts, with an average 12-month price target of $35.57. The company recently exceeded quarterly earnings and revenue expectations, reporting $0.11 EPS against an anticipated $0.06 and $129.86 million in revenue versus $118.85 …

Sei Investments Co. Buys Shares of 99,627 MeiraGTx Holdings PLC $MGTX

Nektar: Q2 Earnings Snapshot

The article provides a snapshot of Nektar's Q2 earnings. No specific financial details are available in the provided content, as the main article text was not included.

Confluence Wealth Services Inc. Acquires 7,986 Shares of Gilead Sciences, Inc. $GILD

Confluence Wealth Services Inc. significantly increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 251.4% during the second quarter, acquiring an additional 7,986 shares, bringing its total holdings to 11,162 shares valued at $1.41 million. Gilead reported strong Q2 revenue of $7.80 billion, exceeding …